The FDA has announced the upcoming discontinuation for Parkinson disease and restless legs syndrome treatment ropinirole hydrochloride (Requip, GlaxoSmithKline).
According to the FDA notice, the non-ergot dopamine agonist will be discontinued in its tablet form as well as some of its extended-release tablet formulations. The therapy is anticipated to cease availability of these forms by May 2023. The FDA notice stated that these discontinuations are the result of a business decision.
I learned of this only when my pharmacy called to say that they could not fill my repeated prescription for 4 x 2mg per day and that they had tried everywhere possible and had sent my Neurologist a telefax asking for an alternative. They had received no prior notification ,and the situation may be the same world wide and I had run out by this point. My wife takes one x 1 mg per day also for Restless legs . My Neuro gave me a new prescription for a different medication which I obtained and very quickly determined that I could not take it.
The Neuro then gave me a prescription for NEUPRO 2 mg PATCH /24 hrs
with the following directions
one patch 2 mg / 24 hours once daily for 14 days
then two patches 2 mg each (total 4 mg) once daily for 14 days
followed by one 6 mg patch / 24 hours, once daily for 14 days
I was concerned about weaning off the Ropinirole cold turkey so we called many drugstores with the advice that older, smaller pharmacies may be the most likely to have some old stock due to a customer dying and no one else requiring it, and this was exactly the case. My neuro then sent the country pharmacy a prescription for a transition amount to let me slowly discontinue taking it.
It is possible that some other manufacturer will jump in and start making it or that a world wide shortage and discontinuation will result or both.
Good Luck